lies.45 Despite the description of the molecular defects, the pathogenesis of the disease remains unclear. We present the contrasting clinical consequences of two mutations in the ,B-MHC gene.
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Methods
Patient Population
The two kindreds, 2755 spouse, underwent evaluation at the NIH that included a 12-lead ECG and echocardiographic examination. Informed consent for the studies was obtained in accordance with study protocols approved by the Institute Review Board of the National Heart, Lung, and Blood Institute.
Echocardiography
Echocardiographic examination was performed with a Hewlett-Packard (Sonos 500 or Sonos 1000) real-time, pulsed-array, 900 ultrasonic scanner with a 2.5-MHz The second method of sequencing involved the production of single-strand template by modification of a method described previously.'3 Briefly, a biotin phosphoramidite (Midland Reagent Co., Midland, Tex.) was used to add a biotin molecule to the 5' end of an oligonucleotide primer in the last step in its synthesis on the nucleic acid synthesizer (model 380B, Applied Biosystems, Foster City, Calif.). This primer, together with its mate that was not biotinolated, was used to generate the PCR-amplified fragment to be sequenced. Twenty microliters of this 
The products of all 40 primer pairs were consistently suitable for analysis. The PCR fragments amplified from DNA of the members of both kindreds were evaluated for the presence of polymorphisms on SSCP gels run at both room temperature and 4°C. Polymorphic fragments were then sequenced directly without subcloning as described in "Methods."
These techniques detected several polymorphisms in both kindreds; however, the sequencing of all the polymorphisms showed that only two reflected changes in exon coding sequence. Each was unique to one of the two kindreds, and both involved the replacement of a highly conserved amino acid. These point mutations in exons 13 (kindred 2002) and 23 (kindred 2755), together with the primer pairs used to amplify them, are depicted in Table 1 .
Identification of the 908Leu-Val Mutation in Kindred 2755. All 40 exons of the f-MHC gene, amplified by PCR from the DNA of a subset of family members, were evaluated on SSCP gels at room temperature and 4°C.
Only the fragment containing exon 23 was found to contain a polymorphism that cosegregated with the disease (Figure 3 ). Direct sequencing of this fragment in both directions showed a C->G transversion resulting in the replacement of a leucine by a valine at amino acid residue 908 ( Figure 4 ). Subsequent sequencing of a cDNA clone from an affected member of the family confirmed this mutation (data not shown). This mutation destroys a Pvu II site, thus lengthening the 140 basepair fragment found in normal individuals to a 161 basepair fragment that is diagnostic of the disease in this kindred. All 19 individuals in this kindred with echocardiographic criteria for HCM had this mutation, which is shown in a subset of the kindred in Figure 5 . This mutation was not seen in a survey of 100 other chromosomes. showed the presence of a polymorphism on an SSCP gel. Direct sequencing of the exon 3-containing fragment showed the mutation to lie outside of the exon and splice consensus sites. Direct sequencing in both directions of the exon 13 fragment detected a G->A transition that resulted in the replacement of an arginine by a glutamine at amino acid residue 403 ( Figure 6 ). This mutation creates a new Dde I restriction enzyme site by changing the sequence CTCGG found in normal individuals to CTCAG, thus shortening the 161 basepair fragment found in normal individuals to a 129 basepair fragment that is found in all affected members of this 11 were young (age, 1-11 years). All the 11 young patients had normal echocardiograms except one 12-year old patient, who had an abnormal 12-lead ECG (narrow deep Q waves in leads III, aVF, and V6). None of the blood relatives in whom the 908 mutation was absent (n -165) or married-in spouses (n -37) had a maximum left ventricular wall thickness of > 12 mm (Figure 7 ). Of the 31 older individuals with the 908 mutation (age, years), 12 had normal echocardiograms with maximum left ventricular wall thickness of 8-12 mm (Table 2) . Figure 8 . Thus, the cumulative sudden deathfree survival rates at 20 and 60 years of age were 97+±3% and 92+6%, respectively ( Figure 8A) . Similarly, the event (sudden death, syncope, or presyncope) -free rates were 95±3% and 90±6%, respectively ( Figure 8B) The 403 mutation was also associated with a high incidence of cardiac events: sudden death in six, syncope in three, and presyncope in four patients. The cumulative sudden death-free rates at 20, 30, and 40 years of age were 90±9%, 68+16%, and 45±17%, respectively ( Figure 8A) . Similarly, the event-free rates at 20, 30, and 40 years of age were only 70±13%, 46±14%, and 8±7%, respectively ( Figure 8B ). A comparison of kindreds 2755 and 2002, each with distinct missense mutations (908LcuVat and 403Arg-GIn respectively) illustrates that the severity and penetrance of the disease may be determined by the specific mutation. Of the 195 members of kindred 2755 who were evaluated clinically, 42 individuals inherited the mutant allele. Of the 31 individuals .17 years of age with the mutant allele, 19 had a maximum left ventricular wall thickness of > 13 mm. In contrast, all 123 blood relatives without the mutant allele as well as 37 unrelated spouses had a maximum left ventricular wall thickness of <12 mm. Thus, 12 adult members with the mutant allele failed to meet this echocardiographic criterion for HCM a definition of HCM that was less stringent than that used traditionally to diagnose the disease (maximum left ventricular wall thickness >15 mmt4). Furthermore, seven of these 12 adults also had normal 12-lead ECGs; hence, the disease penetrance for the adults in this kindred was only 61% when the echocardiographic threshold of >12 mm was used and 77% when ECG analysis was included in the diagnostic criteria. In addition, none of 11 children with the mutant allele had left ventricular hypertrophy on echocardiogram, and only one child, aged 12 years, had an abnormal 12-lead ECG.
In contrast to kindred 2755, all 11 adults in kindred 2002 had left ventricular hypertrophy and abnormal 12-lead ECGs. Moreover, of four children with the mutant allele, two had left ventricular hypertrophy and three had abnormal 12-lead ECGs. The only child with normal cardiac findings was a 9-month-old female patient. Thus, the disease penetrance in this kindred was 100% in adults by echocardiographic criteria and 93% in all ages when the ECG analysis was added to the diagnostic criteria. 
